

Second World Indigenous Peoples' Conference on Viral Hepatitis

Individual response report

Respondent Type:	Anonymous	Custom Data 1:	
Name:		Custom Data 2:	
Email:		Custom Data 3:	
IP Address:	158.145.224.111	Survey Started:	05/25/2017, 06:33 PM GMT
Country:	United States	Survey Ended:	05/25/2017, 11:05 PM GMT

Second World Indigenous Peoples' Conference on Viral Hepatitis - 2017 Call for Abstracts Submission Form

Submission Guidelines

Review and Selection Process

Scholarships

Abstract Form

1. Primary Presenter Information

PLEASE NOTE: As the primary presenter - you will be the point of contact for correspondence with the conference coordinator regarding logistics and coordination of the presentation.

Name	Stephanie C Massay
Credentials (ex: RN, MPH, Student)	MPH, MT(ASCP)
Title	Epidemiology Specialist
Organization	Alaska Section of Epidemiology
Address	3601 C Street, Suite 540
City/Town	Anchorage
State	AK
Zip	99503
Email Address	stephanie.massay@alaska.gov
Phone Number	9072698011

2. Other Presenters

Name	None
Credentials (ex: RN, MPH, Student)	N/A
Title	N/A
Organization	N/A
Address	N/A
City/Town	N/A
State	N/A
Zip	N/A
Email Address	N/A
Phone Number	N/A

3. Other Presenters

Name	None
Credentials (ex: RN, MPH, Student)	N/A
Title	N/A
Organization	N/A
Address	N/A
City/Town	N/A
State	N/A
Zip	N/A
Email Address	N/A
Phone Number	N/A

4. Other Presenters

Name	None
Credentials (ex: RN, MPH, Student)	N/A
Title	N/A
Organization	N/A
Address	N/A
City/Town	N/A
State	N/A
Zip	N/A
Email Address	N/A
Phone Number	N/A

5. Please confirm that you are comfortable presenting in English.

Yes

6. Would you like to be considered for a scholarship?

No

7. Presentation Title:

The impact of universal childhood vaccination on elimination of hepatitis A transmission in Alaska

8. Presentation Category (select from the options below):

Data – burden of disease, prevalence, incidence, immunisation, treatment and outcomes, strategies for getting these data.

9. Abstract (Session Description)

Please do not exceed 500 words. Please provide an overview of the content that you plan to share in your presentation.

Authors: Stephanie Massay, Rosalyn Singleton, Joseph McLaughlin, Dana Bruden, Prabhu Gounder, Brian McMahon

Background: Alaska experienced epidemics of hepatitis A every 10–15 years during the 1950s to the 1990s, resulting in thousands of cases. Alaska Native (AN) people living in rural communities were disproportionately impacted. Hepatitis A virus (HAV) vaccines were licensed in 1995 and recommended by the Advisory Committee on Immunization Practice for routine vaccination of US children in populations with high HAV infection rates. Alaska began universal vaccination for children aged 2–14 years in 1996; HAV vaccination became required for school entrance in 2001.

Methods: Cases of acute hepatitis A during 1972–2016 were obtained from the Alaska Section of Epidemiology AKSTARS database. A confirmed case is defined as an acute illness with discrete onset of symptoms and jaundice, or elevated serum aminotransferase levels, and an IgM antibody to HAV or an epidemiological link to a person with laboratory-confirmed hepatitis A. Vaccine coverage estimates were obtained from the National Immunization Survey (NIS). Cases were summarized by race, region, and age group. Denominators were derived using 2000 and 2010 U.S. census data.

Results: During 1972–1995, Alaska's average annual incidence of hepatitis A was 60 per 100,000 population (range: 3.4–386.9). Rates by race were substantially higher for AN people compared to non-AN people (243.8 vs 19.2, respectively; relative risk (RR) 12.7, $p < 0.001$). Compared to 1972–1995 (pre-vaccine), the 2002–2007 (post-vaccine) statewide hepatitis A incidence was 98.4% lower (0.9 vs. 60 per 100,000, respectively; RR 0.016) and the AN incidence was 99.9% lower (0.3 vs. 243.8 per 100,000, respectively; RR 0.001). During 2008–2016, 23 HAV cases were reported in Alaska; 5 among AN, 11 in non-AN, and 7 among people of unknown race/ethnicity. The 2008–2016 statewide incidence of hepatitis A was 0.35 cases per 100,000 people; the incidence in children aged <14 years was 0.14 cases per 100,000 children. The statewide incidence did not vary significantly by region (range: 0.0–0.61 cases per 100,000 persons). Of the 17 cases with documentation on travel, 15 (88%) had recent travel outside of Alaska. The 2015 NIS estimated 19–35 month 1+ dose HAV vaccine coverage was similar in Alaska and all US children (83.5+4.9 vs. 85.8+1.1).

Discussion: Dramatic declines in the incidence of hepatitis A occurred after HAV vaccine was recommended as a routine childhood vaccine and after it was required for school entry. Since 2008, 88% of reported hepatitis A cases were associated with out-of-state travel.

398 words

10. Presentation Preference Type:

Workshop Session - Presentation Style (30 - 50 people)

11. Learning objectives: Please specify which of the following conference goals relates best to your session (select all that apply):

Describe how to discuss and document our knowledge of the prevalence of hepatitis viruses in Indigenous Peoples across the globe.

12. If your abstract were to be selected for oral presentation please specify 3-5 SMART (Specific, Measurable, Attainable, Realistic, Trackable) objectives for your presentation that meet the conference goals.

Review the epidemiology of Hepatitis A virus infection in Alaska
Discuss impact of Hep A vaccine use in reducing the incidence of disease among Alaska Native people
Describe the immunization strategies used in Alaska and why they have been successful

13. Primary Presenter Biography (please introduce yourself in 100-200 words):

Stephanie Massay is the Vaccine-Preventable Disease Surveillance Coordinator for the Alaska Division of Public Health, Section of Epidemiology, Infectious Disease Program. She is a board-certified medical technologist with over twenty years of clinical and public health practice experience in Alaska working in a variety of settings. As the VPD Surveillance Coordinator, she is responsible for developing standards for documenting VPD investigations, assisting in disease investigations, collecting and reporting surveillance data, preparing reports of VPD surveillance data, and developing outreach materials and possible public health interventions based upon data findings.

14. Presenter #2 Biography (please introduce yourself in 100-200 words):

N/A

15. Presenter #3 Biography (please introduce yourself in 100-200 words):

N/A

16. Presenter #4 Biography (please introduce yourself in 100-200 words):

N/A